Soleus Capital Management L.P. Has $15.62 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)

Soleus Capital Management L.P. grew its position in Pharvaris (NASDAQ:PHVS - Free Report) by 36.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 814,652 shares of the company's stock after acquiring an additional 216,483 shares during the period. Soleus Capital Management L.P. owned 1.56% of Pharvaris worth $15,617,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of PHVS. Barclays PLC bought a new position in Pharvaris during the 3rd quarter worth $106,000. Palumbo Wealth Management LLC bought a new position in Pharvaris during the 4th quarter worth $196,000. KLP Kapitalforvaltning AS bought a new position in Pharvaris during the 4th quarter worth $111,000. JPMorgan Chase & Co. raised its position in Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after purchasing an additional 1,356 shares during the last quarter.

Pharvaris Stock Down 2.4%

Pharvaris stock traded down $0.40 during trading hours on Friday, reaching $15.99. 16,327 shares of the company's stock were exchanged, compared to its average volume of 72,851. The firm's 50 day simple moving average is $15.39 and its 200 day simple moving average is $17.41. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The firm has a market capitalization of $836.12 million, a PE ratio of -5.71 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). Analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on PHVS shares. Cantor Fitzgerald lowered their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. JMP Securities raised their target price on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.